Global EPA+DHA Omega-3 Finished Products Report: Data for 2020 and 2021 with Forecasts Through 2023 - ResearchAndMarkets.com
25 Nov 2022
DUBLIN--(BUSINESS WIRE)--The "The Global EPA+DHA Omega-3 Finished Products Report - Data for 2020 and 2021 with forecasts through 2023" report has been added to ResearchAndMarkets.com's offering.
'The Global EPA+DHA Omega-3 Finished Products Report - Data for 2020 and 2021 with forecasts through 2023'
The EPA and DHA omega-3 finished product market size reached US$47 billion in 2021. Growth remains strongest in developing markets in Asia, Africa, and the Middle East, leading the global EPA and DHA consumer product market to a projected annual growth rate of 3.2% for 2022-2023.
How can I learn more?
The Finished Product Report provides a description of the size and value of the global finished product market for EPA and DHA oils. For the purposes of this report, an omega-3 finished product is a product containing EPA and/or DHA omega-3s, which are often used as an ingredient in dietary supplements, fortified foods and beverages, pharmaceuticals, clinical nutrition/medical food, infant formula and pet food/supplements.
Finished product sales estimates and projections are detailed by finished product category. The report also includes forecasts through 2023 and an analysis of the geographic trends and factors influencing market growth.
Charts and figures include:
Figures by Region
United States
Canada
Mexico
South America
Europe
Australia
New Zealand
China
Japan
Rest of APAC
Rest of Asia
Rest of World
Figures by Finished Product Category
Dietary Supplement
Pharmaceutical
Key Topics Covered:
Scope and Methodology
Scope
Report Methodology
Market Overview
Regional Trends
Product Category Trends
Major Market Dynamics
Food and Beverage
Pharmaceuticals
Clinical Nutrition and Medical Food
Sales + Growth by Product Category
Sales by Region
Acknowledgements
About the Report
For more information about this report visit https://www.researchandmarkets.com/r/s26ggd
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.